HIGHLIGHTS
- who: Steffen Berweck and colleagues from the Schön Klinik Vogtareuth, Krankenhausstraße, Vogtareuth, Germany Drvon Children's Hospital, Munich University, Lindwurmstrasse, Munich, Germany have published the Article: Safety Profile and Lack of Immunogenicity of IncobotulinumtoxinA in Pediatric Spasticity and Sialorrhea: A Pooled Analysis, in the Journal: (JOURNAL)
- what: This analysis provides safety data from phase 3 trials of children/adolescents (2-17 years) investigating incobotulinumtoxinA for the treatment of associated with cerebral palsy (at doses ≤20 U/kg (max. One subject with spasticity in the TIM trial, who was HDA-positive at screening but . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.